On Oct. 27, 2020, Novavax announced updates on its Phase 3 clinical development program of NVX-CoV2373, its COVID-19 vaccine candidate. NVX-CoV2373 is a stable, prefusion protein made using Novavax nanoparticle technology and includes Novavax proprietary Matrix-M adjuvant.

Novavax had enrolled over 5,500 participants to date in the UK trial, which it was expanded to 15,000 volunteers.